advertisement
Abstract #5808 Published in IGR 2-1
The ocular hypotensive effect of the combination of latanoprost with dorzolamide
Chiselita D; Apatachioae I; Poiata IOftalmologia 1999; 46:39-45
OBJECTIVE: To analyze the hypotensive effect and ocular tolerance produced by the association of a topic carbonic anhidraze inhibitor (dorzolamide; Trusopt) and a prostaglandin derivative (latanoprost; Xalatan) in the treatment of the hypertensive glaucomas. MATERIAL AND METHODS: The study includes two steps: Step 1: A double-blind randomized prospective study which includes 32 eyes with primary open angle glaucoma, divided in two groups: group A, in which Trusopt is administered for seven days and then Xalatan is added for another seven days; and group B, in which the order is reversed: for the first seven days only Xalatan is administered and then Trusopt is added for another seven days. The intraocular pressure and secondary effects were assessed daily. Step 2: An open clinical trial that included 47 eyes with different types of glaucomas in which the combination Trusopt + Xalatan was used for 90 days. The intraocular pressure and the secondary effects were assessed weekly. RESULTS: In the first study (step 1) the combination Trusopt + Xalatan induced an added type of ocular hypotensive effect, which was not dependent on the order of the two drugs used at the start of treatment (37.49% for group A and 39.16% for group B). In the clinical trial for medium term (step 2), the combination Trusopt + Xalatan resulted in a decrease in IOP, which varied between 27.94% and 37.02% and was stable during the entire period of the study. The following secondary effects were observed: conjunctival hyperemia (six cases), burning sensation (three cases), foreign body sensation (one case), itching (two cases), and hazing (one case). CONCLUSIONS: The association Trusopt + Xalatan results in an added ocular hypotensive effect which was stable for the entire study period (medium term). Ocular tolerance with this combination was good and was not followed by interruption of the treatment. LA: <#>
Dr. D. Chiselita, Clinica de Oftalmologie, Spitalul Sf. Spiridon, Iasi <#>
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)
11.5.2 Topical (Part of: 11 Medical treatment > 11.5 Carbonic anhydrase inhibitors)
